argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111

On June 2, 2016 Argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, reported data published in conjunction with the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2016 Annual Meeting (Chicago, USA) presenting efficacy and safety data from its ARGX-111 Phase 1 expansion study in patients with MET amplified tumors (Press release, arGEN-X, JUN 2, 2016, View Source [SID:1234512983]). The data confirm ARGX-111 to have a favorable safety profile and to continue to show signs of anti-tumor activity. The abstract can be accessed here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, data from preclinical studies demonstrate depletion of MET-positive myeloid-derived suppressor cells (MDSCs) by ARGX-111. These data provide an exciting new perspective for therapeutic intervention in MET cancer biology in targeting both the tumor cells and the tumor microenvironment.

About ARGX-111

ARGX-111 is a Met-targeting human monoclonal SIMPLE Antibody that modulates all known mechanisms of action of the receptor. ARGX-111 benefits from POTELLIGENT-enhanced Antibody Dependent Cellular Cytotoxicity (ADCC), which drives the immune system to destroy
c-MET positive cells of the primary tumor and the circulating tumor cells that are responsible for metastasis; and from NHance, which is thought to drive tissue penetration. This unique combination results in a potentially best-in-class drug candidate for c-Met therapies. ARGX-111 is tested in a Phase 1 safety expansion cohort in MET-amplified patients.